Mood Disorders

Future use of a 12-hour standardized lithium serum concentration notation: the first step towards more interpretable scientific literature and the return of the therapeutic importance of lithium.

These partnerships aim to address the mental health needs of underserved populations, including individuals with clinical depression, anxiety, and mood disorders.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

Psychiatric Times chats with new Mood Disorders Section Editor Gus Alva, MD, about his new role, his interest in mood disorders, and his love of psychiatry.

Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?

The Psymatic Treatment Optimizer facilitates selecting agents ranked by adverse-effect profile with consideration of patient preference and tolerance.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.

What is new in research on sleep?

How does a patient process their illness and move their way to healing and even creativity?

Black mothers in the US experience far worse outcomes. Here’s what clinicians need to know.

What is the association between the gut microbiome and response to SSRIs in patients with depression?

1 in 5 respondents reported using psychedelic drugs for the purpose of self-treating anxiety, depression, or other mental illnesses.

Check out the evidence for a modest effect over 1 year of clozapine dose on weight.

PME affects many women, yet it remains under-recognized in clinical practice and in research.

In Part III of this series, an expert discusses the key differences between cyclothymia and borderline personality disorder, along with treatment considerations for cyclothymia.

In Part II of this series, an expert discusses cyclothymia and mood temperament in children and adolescents.

In Part I of this new series, an expert provides an overview of cyclothymia and mood temperaments.

What is the current role of lithium?

Catatonia is thought to be significantly underrecognized, and it is important to routinely screen for it among hospitalized patients. Here's how to recognize and treat.

What is the best evidence-based medication treatment for acute bipolar II depression?

Lithium: what’s its history and where do we still need more information?

Catatonia: learn more about how to best diagnose early.

Data on the effects of discontinuing lithium on renal function are scarce and conflicting. A new study exploring these effects may aid in the clinical decision-making process.

From the effects of caffeine on smokers with schizophrenia and bipolar disorder to the initiation of a trial for a new ADHD medication, here are highlights from the week in Psychiatric Times.

Smoking and drinking (caffeine): Researchers analyzed caffeine intake and levels in smokers with schizophrenia and bipolar disorder.

"This study served as a sobering reminder of the significant frequency of this disfiguring and sometimes disabling adverse effect, which can be irreversible."